{"id":"https://openalex.org/W2004702080","doi":"https://doi.org/10.1358/dnp.2004.17.4.829052","title":"mGlu5 receptor antagonists: A novel class of anxiolytics?","display_name":"mGlu5 receptor antagonists: A novel class of anxiolytics?","alternate_titles":[],"publication_year":2004,"publication_date":"2004-05-01","ids":{"openalex":"https://openalex.org/W2004702080","doi":"https://doi.org/10.1358/dnp.2004.17.4.829052","mag":"2004702080","pmid":"https://pubmed.ncbi.nlm.nih.gov/15334174"},"language":"en","primary_location":{"id":"doi:10.1358/dnp.2004.17.4.829052","doi":"https://doi.org/10.1358/dnp.2004.17.4.829052","is_oa":false,"landing_page_url":"https://doi.org/10.1358/dnp.2004.17.4.829052","pdf_url":null,"source":{"id":"https://openalex.org/S51538572","display_name":"Drug News & Perspectives","issn_l":"0214-0934","issn":["0214-0934","2013-0139"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","jufo-1"],"host_organization":null,"host_organization_name":null,"host_organization_lineage":[],"host_organization_lineage_names":[],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Drug News &amp; Perspectives","raw_type":"journal-article"},"parent_works":[],"lineage":["https://openalex.org/W2004702080"],"child_works_count":0,"type":"article","is_traditional":true,"indexed_in":["crossref","pubmed"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5051611586","display_name":"Will P. J. M. Spooren","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I118019719","display_name":"F. Hoffmann-La Roche AG","ror":"https://ror.org/00by1q217","country_code":"CH","type":"company","lineage":["https://openalex.org/I118019719"]}],"countries":["CH"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"W. Spooren","raw_affiliation_strings":["F. Hoffmann-La Roche, Pharma Research Basel Discovery, Neuroscience, Basel, Switzerland. will.spooren@roche.com"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"F. Hoffmann-La Roche, Pharma Research Basel Discovery, Neuroscience, Basel, Switzerland. will.spooren@roche.com","institution_ids":["https://openalex.org/I118019719"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5032192926","display_name":"Fabrizio Gasparini","orcid":"https://orcid.org/0000-0002-1315-563X","observed_orcids":["https://orcid.org/0000-0002-1315-563X"]},"institutions":[],"countries":[],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"F. Gasparini","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":1,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":3.5854,"has_fulltext":false,"cited_by_count":91,"citation_normalized_percentile":{"value":0.93793561,"is_in_top_1_percent":false,"is_in_top_10_percent":true},"cited_by_percentile_year":{"min":88,"max":98},"biblio":{"volume":"17","issue":"4","first_page":"251","last_page":"251"},"is_retracted":false,"is_pulled":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10077","display_name":"Neuroscience and Neuropharmacology Research","score":0.9897000193595886,"subfield":{"id":"https://openalex.org/subfields/2804","display_name":"Cellular and Molecular Neuroscience"},"field":{"id":"https://openalex.org/fields/28","display_name":"Neuroscience"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},"topics":[{"id":"https://openalex.org/T10077","display_name":"Neuroscience and Neuropharmacology Research","score":0.9897000193595886,"subfield":{"id":"https://openalex.org/subfields/2804","display_name":"Cellular and Molecular Neuroscience"},"field":{"id":"https://openalex.org/fields/28","display_name":"Neuroscience"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T11071","display_name":"Treatment of Major Depression","score":0.003700000001117587,"subfield":{"id":"https://openalex.org/subfields/2736","display_name":"Pharmacology (medical)"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10056","display_name":"Neurotransmitter Receptor Influence on Behavior","score":0.0020000000949949026,"subfield":{"id":"https://openalex.org/subfields/2804","display_name":"Cellular and Molecular Neuroscience"},"field":{"id":"https://openalex.org/fields/28","display_name":"Neuroscience"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/mglu5-receptor-antagonists","display_name":"mGlu5 receptor antagonists","score":0.9179999828338623},{"id":"https://openalex.org/keywords/metabotropic-glutamate-receptors","display_name":"metabotropic glutamate receptors","score":0.9929999709129333},{"id":"https://openalex.org/keywords/anxiolytic-effects","display_name":"anxiolytic effects","score":0.8939999938011169},{"id":"https://openalex.org/keywords/mpep","display_name":"MPEP","score":0.972000002861023},{"id":"https://openalex.org/keywords/benzodiazepine-alternatives","display_name":"benzodiazepine alternatives","score":0.8009999990463257},{"id":"https://openalex.org/keywords/g-protein-coupled-receptors","display_name":"G protein-coupled receptors","score":0.9150000214576721},{"id":"https://openalex.org/keywords/glutamatergic-neurotransmission","display_name":"glutamatergic neurotransmission","score":0.8659999966621399},{"id":"https://openalex.org/keywords/cns-drug-targets","display_name":"CNS drug targets","score":0.625}],"concepts":[{"id":"https://openalex.org/C26702167","wikidata":"https://www.wikidata.org/wiki/Q901988","display_name":"Metabotropic receptor","level":4,"score":0.7086045742034912},{"id":"https://openalex.org/C189184402","wikidata":"https://www.wikidata.org/wiki/Q3454536","display_name":"Kainate receptor","level":5,"score":0.7026063799858093},{"id":"https://openalex.org/C170493617","wikidata":"https://www.wikidata.org/wiki/Q208467","display_name":"Receptor","level":2,"score":0.6458911299705505},{"id":"https://openalex.org/C203270574","wikidata":"https://www.wikidata.org/wiki/Q24725121","display_name":"Class C GPCR","level":5,"score":0.6353505849838257},{"id":"https://openalex.org/C49051014","wikidata":"https://www.wikidata.org/wiki/Q2033959","display_name":"Metabotropic glutamate receptor","level":4,"score":0.6102014780044556},{"id":"https://openalex.org/C160268369","wikidata":"https://www.wikidata.org/wiki/Q295251","display_name":"AMPA receptor","level":4,"score":0.5988609790802002},{"id":"https://openalex.org/C61174792","wikidata":"https://www.wikidata.org/wiki/Q420510","display_name":"Glutamate receptor","level":3,"score":0.5841066837310791},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.5707355737686157},{"id":"https://openalex.org/C115955781","wikidata":"https://www.wikidata.org/wiki/Q6063798","display_name":"Ionotropic effect","level":4,"score":0.5670590400695801},{"id":"https://openalex.org/C73009533","wikidata":"https://www.wikidata.org/wiki/Q1517140","display_name":"Long-term depression","level":5,"score":0.48625218868255615},{"id":"https://openalex.org/C200170125","wikidata":"https://www.wikidata.org/wiki/Q969316","display_name":"Neurotransmission","level":3,"score":0.4536813795566559},{"id":"https://openalex.org/C169760540","wikidata":"https://www.wikidata.org/wiki/Q207011","display_name":"Neuroscience","level":1,"score":0.4374798834323883},{"id":"https://openalex.org/C2780648746","wikidata":"https://www.wikidata.org/wiki/Q28208871","display_name":"Glutamatergic","level":4,"score":0.4297420382499695},{"id":"https://openalex.org/C88272193","wikidata":"https://www.wikidata.org/wiki/Q418536","display_name":"Ion channel linked receptors","level":5,"score":0.42714235186576843},{"id":"https://openalex.org/C86803240","wikidata":"https://www.wikidata.org/wiki/Q420","display_name":"Biology","level":0,"score":0.37713176012039185},{"id":"https://openalex.org/C185592680","wikidata":"https://www.wikidata.org/wiki/Q2329","display_name":"Chemistry","level":0,"score":0.37205326557159424},{"id":"https://openalex.org/C55493867","wikidata":"https://www.wikidata.org/wiki/Q7094","display_name":"Biochemistry","level":1,"score":0.2021089494228363}],"mesh":[{"descriptor_ui":"D000818","descriptor_name":"Animals","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D001007","descriptor_name":"Anxiety","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":false},{"descriptor_ui":"D001665","descriptor_name":"Binding Sites","qualifier_ui":"Q000187","qualifier_name":"drug effects","is_major_topic":false},{"descriptor_ui":"D001923","descriptor_name":"Brain Chemistry","qualifier_ui":"Q000187","qualifier_name":"drug effects","is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D011725","descriptor_name":"Pyridines","qualifier_ui":"Q000378","qualifier_name":"metabolism","is_major_topic":false},{"descriptor_ui":"D014151","descriptor_name":"Anti-Anxiety Agents","qualifier_ui":"Q000494","qualifier_name":"pharmacology","is_major_topic":true},{"descriptor_ui":"D014151","descriptor_name":"Anti-Anxiety Agents","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":false},{"descriptor_ui":"D018094","descriptor_name":"Receptors, Metabotropic Glutamate","qualifier_ui":"Q000037","qualifier_name":"antagonists & inhibitors","is_major_topic":true},{"descriptor_ui":"D018691","descriptor_name":"Excitatory Amino Acid Antagonists","qualifier_ui":"Q000494","qualifier_name":"pharmacology","is_major_topic":true},{"descriptor_ui":"D018691","descriptor_name":"Excitatory Amino Acid Antagonists","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":false},{"descriptor_ui":"D064529","descriptor_name":"Receptor, Metabotropic Glutamate 5","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false}],"locations_count":2,"locations":[{"id":"doi:10.1358/dnp.2004.17.4.829052","doi":"https://doi.org/10.1358/dnp.2004.17.4.829052","is_oa":false,"landing_page_url":"https://doi.org/10.1358/dnp.2004.17.4.829052","pdf_url":null,"source":{"id":"https://openalex.org/S51538572","display_name":"Drug News & Perspectives","issn_l":"0214-0934","issn":["0214-0934","2013-0139"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","jufo-1"],"host_organization":null,"host_organization_name":null,"host_organization_lineage":[],"host_organization_lineage_names":[],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Drug News &amp; Perspectives","raw_type":"journal-article"},{"id":"pmid:15334174","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/15334174","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Drug news & perspectives","raw_type":"Journal Article"}],"best_oa_location":null,"sustainable_development_goals":[{"score":0.9391000270843506,"display_name":"Good health and well-being","id":"https://metadata.un.org/sdg/3"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W1933765091","https://openalex.org/W1986434830","https://openalex.org/W2061070984","https://openalex.org/W1978157729","https://openalex.org/W2233987578","https://openalex.org/W2124768361","https://openalex.org/W2145727779","https://openalex.org/W2071203240","https://openalex.org/W2084903264","https://openalex.org/W2061833071"],"abstract_inverted_index":{"In":[0,66],"the":[1,16,30,69,96,103,113,116,133,169,193,196,209,216,236],"early":[2],"1990s,":[3],"a":[4,92,125,184],"new":[5,126],"family":[6],"of":[7,20,129,135,142,150,168,171,181,195,199,202,211],"receptors":[8,37,58,86,118,149,173],"were":[9,12],"cloned":[10,43],"that":[11,28,115,145],"found":[13],"to":[14,24,39,44,48,68,90,148,227],"mediate":[15],"intracellular":[17],"metabolic":[18],"effects":[19],"glutamate":[21,32],"via":[22],"coupling":[23],"secondary":[25],"messenger":[26],"systems,":[27],"is,":[29],"metabotropic":[31],"(mGlu)":[33],"receptors.":[34],"Eight":[35],"such":[36],"(mGlu1":[38,153],"mGlu8)":[40],"have":[41,59,87],"been":[42,60,88],"date,":[45],"and":[46,54,75,154,156,160,177,187,218],"according":[47],"their":[49],"amino":[50],"acid":[51],"sequence,":[52],"pharmacology":[53],"second-messenger":[55],"coupling,":[56],"these":[57,172],"clustered":[61],"into":[62,241],"three":[63],"groups":[64],"(I-III).":[65],"contrast":[67],"glutamate-gated":[70],"ion":[71,104],"channels":[72],"(NMDA,":[73],"AMPA":[74],"kainate":[76],"receptors),":[77],"which":[78],"are":[79,119],"responsible":[80],"for":[81,132],"fast":[82],"excitatory":[83],"transmission,":[84],"mGlu":[85,117],"shown":[89],"play":[91],"modulatory":[93],"role":[94],"in":[95,165,174,223,244],"glutamatergic":[97],"synaptic":[98],"transmission":[99],"either":[100],"by":[101,108],"modulating":[102],"channel":[105],"activity":[106,222,243],"or":[107],"influencing":[109],"neurotransmitter":[110],"release.":[111],"Given":[112],"fact":[114],"G-protein-":[120],"coupled,":[121],"they":[122],"obviously":[123],"constitute":[124],"attractive":[127],"group":[128,151,157],"\"drugable\"":[130],"targets":[131],"treatment":[134],"various":[136],"CNS":[137],"disorders.":[138],"The":[139,179],"recent":[140],"discovery":[141],"small":[143],"molecules":[144],"selectively":[146],"bind":[147],"I":[152],"mGlu5)":[155],"II":[158],"(mGlu2":[159],"mGlu3)":[161],"allowed":[162,192],"significant":[163],"advances":[164],"our":[166],"understanding":[167],"roles":[170],"brain":[175],"physiology":[176],"pathophysiology.":[178],"identification":[180],"MPEP":[182],"(2-methyl-6-(phenylethynyl)-pyridine),":[183],"highly":[185],"selective":[186],"brain-penetrant":[188],"mGlu5":[189],"receptor":[190,213],"antagonist,":[191],"exploration":[194],"therapeutic":[197],"potential":[198],"this":[200],"class":[201],"compounds.":[203],"Subsequent":[204],"behavior":[205],"studies":[206,231],"revealed":[207],"that--with":[208],"exception":[210],"benzodiazepines--mGlu5":[212],"antagonists":[214],"exhibit":[215],"widest":[217],"most":[219],"robust":[220],"anxiolytic":[221,242],"preclinical":[224,237],"models":[225],"seen":[226],"date.":[228],"Upcoming":[229],"clinical":[230],"will":[232],"soon":[233],"indicate":[234],"if":[235],"anxiolytic-like":[238],"efficacy":[239],"translates":[240],"humans.":[245]},"cited_by_api_url":"https://api.openalex.org/works?filter=cites:W2004702080","counts_by_year":[{"year":2025,"cited_by_count":1},{"year":2024,"cited_by_count":1},{"year":2023,"cited_by_count":1},{"year":2022,"cited_by_count":2},{"year":2020,"cited_by_count":2},{"year":2019,"cited_by_count":1},{"year":2017,"cited_by_count":4},{"year":2016,"cited_by_count":3},{"year":2015,"cited_by_count":2},{"year":2014,"cited_by_count":1},{"year":2013,"cited_by_count":2},{"year":2012,"cited_by_count":7}],"updated_date":"2026-11-16T12:05:36.265796","created_date":"2016-06-24T00:00:00"}
